Literature DB >> 18499340

2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1.

Hyang-Min Byun1, Si Ho Choi, Peter W Laird, Binh Trinh, Maqbool A Siddiqui, Victor E Marquez, Allen S Yang.   

Abstract

2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine (NPEOC-DAC), decitabine with a modification of the N4 position of the azacitidine ring can be used to inhibit DNA methyltransferase. This modification protects the azacitidine ring and can be cleaved by carboxylesterase to release decitabine. NPEOC-DAC was 23-fold less potent at low doses (<10microM) than decitabine at inhibiting DNA methylation, and was also associated with a 3-day delay in its effect. However, at doses > or = 10microM NPEOC-DAC was more effective at inhibiting DNA methylation. Theses differences between decitabine and NPEOC-DAC are dependent on the cleavage of the carboxylester bond, and could be potentially exploited pharmacologically.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18499340      PMCID: PMC2528876          DOI: 10.1016/j.canlet.2008.02.069

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  44 in total

Review 1.  The clinical application of targeting cancer through histone acetylation and hypomethylation.

Authors:  Jill Gilbert; Steve D Gore; James G Herman; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

2.  Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine.

Authors:  S M Taylor; P A Jones
Journal:  Cell       Date:  1979-08       Impact factor: 41.582

3.  The effect of 5-azacytidine on E. coli DNA methylase.

Authors:  S Friedman
Journal:  Biochem Biophys Res Commun       Date:  1979-08-28       Impact factor: 3.575

4.  Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells.

Authors:  S Grant; K Bhalla; M Gleyzer
Journal:  Leuk Res       Date:  1986       Impact factor: 3.156

5.  Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.

Authors:  C J van Groeningen; A Leyva; A M O'Brien; H E Gall; H M Pinedo
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

6.  A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.

Authors:  C G Moertel; J Rubin; M J O'Connell; A J Schutt; H S Wieand
Journal:  J Clin Oncol       Date:  1986-07       Impact factor: 44.544

7.  Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions.

Authors:  R E Notari; J L DeYoung
Journal:  J Pharm Sci       Date:  1975-07       Impact factor: 3.534

8.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

9.  Specific effects of 5-fluoropyrimidines and 5-azapyrimidines on modification of the 5 position of pyrimidines, in particular the synthesis of 5-methyluracil and 5-methylcytosine in nucleic acids.

Authors:  K Randerath; W C Tseng; J S Harris; L J Lu
Journal:  Recent Results Cancer Res       Date:  1983

10.  The effect of nordihydroguaiaretic acid and related lignans on formyltetrahydrofolate synthetase and carboxylesterase.

Authors:  K M Schegg; W Welch
Journal:  Biochim Biophys Acta       Date:  1984-07-31
View more
  9 in total

Review 1.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

Review 2.  Targeting DNA methylation for epigenetic therapy.

Authors:  Xiaojing Yang; Fides Lay; Han Han; Peter A Jones
Journal:  Trends Pharmacol Sci       Date:  2010-09-16       Impact factor: 14.819

3.  Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy.

Authors:  Mingqing Tang; William Xu; Qizhao Wang; Weidong Xiao; Ruian Xu
Journal:  Curr Genomics       Date:  2009-08       Impact factor: 2.236

4.  A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.

Authors:  Jharna Datta; Kalpana Ghoshal; William A Denny; Swarna A Gamage; Darby G Brooke; Pasit Phiasivongsa; Sanjeev Redkar; Samson T Jacob
Journal:  Cancer Res       Date:  2009-05-05       Impact factor: 12.701

5.  Linking yeast Gcn5p catalytic function and gene regulation using a quantitative, graded dominant mutant approach.

Authors:  Amanda M Lanza; John J Blazeck; Nathan C Crook; Hal S Alper
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

6.  Epigenetic therapy in allogeneic hematopoietic stem cell transplantation.

Authors:  Qaiser Bashir; Basem Magdy William; Guillermo Garcia-Manero; Marcos de Lima
Journal:  Rev Bras Hematol Hemoter       Date:  2013

7.  Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.

Authors:  Amy Ziemba; Eugene Hayes; Burgess B Freeman; Tao Ye; Giuseppe Pizzorno
Journal:  Chemother Res Pract       Date:  2011-12-18

Review 8.  Non-edible plants as an attractive source of compounds with chemopreventive potential.

Authors:  Seungwon Ji; Barbora Orlikova; Marc Diederich
Journal:  J Cancer Prev       Date:  2014-03

9.  Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.

Authors:  Sue Ping Lim; Raman Kumar; Yamini Akkamsetty; Wen Wang; Kristen Ho; Paul M Neilsen; Diego J Walther; Rachel J Suetani; Clive Prestidge; David F Callen
Journal:  BMC Cancer       Date:  2013-03-13       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.